Anthracyclines-paclitaxel combinations in the treatment of breast cancer

被引：15
作者：
Conte, PF
Gennari, A
机构：
[1] U.O. Oncologia Medica, Ospedale Santa Chiara, 56100 Pisa
来源：
ANNALS OF ONCOLOGY | 1997年 / 8卷 / 10期
关键词：
breast cancer; taxol-anthracycline combination;
D O I：
10.1023/A:1008208002779
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
[No abstract available]
引用
收藏
页码：939 / 943
页数：5
相关论文
共 53 条
  • [1] CHEMOTHERAPY AND SURVIVAL IN ADVANCED BREAST-CANCER - THE INCLUSION OF DOXORUBICIN IN COOPER TYPE REGIMENS
    AHERN, RP
    SMITH, IE
    EBBS, SR
    [J]. BRITISH JOURNAL OF CANCER, 1993, 67 (04) : 801 - 805
  • [2] Schedule-dependent interaction between paclitaxel and doxorubicin in human cancer cell lines in vitro
    Akutsu, M
    Kano, Y
    Tsunoda, S
    Suzuki, K
    Yazawa, Y
    Miura, Y
    [J]. EUROPEAN JOURNAL OF CANCER, 1995, 31A (13-14) : 2341 - 2346
  • [3] AMADORI D, 1996, ANN ONCOL S11, V23, P16
  • [4] Dose-response relationship of epirubicin in the treatment of postmenopausal patients with metastatic breast cancer: A randomized study of epirubicin at four different dose levels performed by the Danish Breast Cancer Cooperative Group
    Bastholt, L
    Dalmark, M
    Gjedde, SB
    Pfeiffer, P
    Pedersen, D
    Sandberg, E
    Kjaer, M
    Mouridsen, HT
    Rose, C
    Nielsen, OS
    Jakobsen, P
    Bentzen, SM
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1996, 14 (04) : 1146 - 1155
  • [5] BENGALA C, IN PRESS CANCER
  • [6] PHARMACOKINETICS OF TAXOL AND DOXORUBICIN ADMINISTERED ALONE AND IN COMBINATION BY CONTINUOUS 72-HOUR INFUSION
    BERG, SL
    COWAN, KH
    BALIS, FM
    FISHERMAN, JS
    DENICOFF, AM
    HILLIG, M
    POPLACK, DG
    OSHAUGHNESSY, JA
    [J]. JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1994, 86 (02) : 143 - 145
  • [7] DRUGS 10 YEARS LATER - EPIRUBICIN
    BONADONNA, G
    GIANNI, L
    SANTORO, A
    BONFANTE, V
    BIDOLI, P
    CASALI, P
    DEMICHELI, R
    VALAGUSSA, P
    [J]. ANNALS OF ONCOLOGY, 1993, 4 (05) : 359 - 369
  • [8] BONNETERRE J, 1996, P AN M AM SOC CLIN, V15, P82
  • [9] Doubling epirubicin dose intensity (100 mg/m(2) versus 50 mg/m(2)) in the FEC regimen significantly increases response rates. An international randomised phase III study in metastatic breast cancer
    Brufman, G
    Colajori, E
    Ghilezan, N
    Lassus, M
    Martoni, A
    Perevodchikova, N
    Tosello, C
    Viaro, D
    Zielinski, C
    Krainer, M
    Salzer, H
    Schuller, J
    Dittrich, C
    Scheithauer, W
    Zamagni, C
    Ambrosini, G
    Colucci, G
    Gentilini, P
    Zaniboni, A
    Pacini, P
    Bianco, R
    Mustacchi, G
    DAprile, M
    DeMatteis, A
    Oliveira, C
    Jordaan, J
    Gudgeon, A
    VanZyl, J
    Rakowsky, E
    Inbar, M
    Rath, P
    Cohen, Y
    Shani, A
    Fried, G
    Hegg, R
    Neto, AB
    Bader, G
    Braga, RF
    Vitoc, C
    Puerto, VML
    Valle, AE
    Salazar, JD
    Sanchez, JC
    Villela, GM
    Fountzilas, G
    [J]. ANNALS OF ONCOLOGY, 1997, 8 (02) : 155 - 162
  • [10] BURGEOIS H, 1996, P AN M AM SOC CLIN, V15, P258
123456